论文部分内容阅读
EntreMed宣布开始MKC-1治疗晚期胰腺癌的多中心Ⅱ期临床试验。此次试验的首要目的是确定MKC-1口服制剂是否对先前至少经历过一次化疗后失败的不可切除性或转移性胰腺癌有抗癌活性。同时还将评估其对胰腺癌患者的安全性、耐受性和总体中位生存期。
EntreMed Announces Multicenter Phase II Trial of MKC-1 for Advanced Pancreatic Cancer. The primary objective of this trial was to determine if the MKC-1 oral formulation had anticancer activity on unresectable or metastatic pancreatic cancer that had previously undergone a single chemotherapy failure. It will also assess its safety, tolerability and overall median survival for patients with pancreatic cancer.